z-logo
open-access-imgOpen Access
M i R ‐21 Modulates h TERT Through a STAT 3‐Dependent Manner on Glioblastoma Cell Growth
Author(s) -
Wang YingYi,
Sun Guan,
Luo Hui,
Wang XieFeng,
Lan FengMing,
Yue Xiao,
Fu LinShan,
Pu PeiYu,
Kang ChunSheng,
Liu Ning,
You YongPing
Publication year - 2012
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/j.1755-5949.2012.00349.x
Subject(s) - telomerase reverse transcriptase , cell growth , chromatin immunoprecipitation , chemistry , telomerase , stat3 , gene knockdown , microbiology and biotechnology , cancer research , signal transduction , biology , apoptosis , gene expression , gene , promoter , biochemistry
Summary Background and purpose As an important oncogenic mi RNA , mi R ‐21 has been reported to play crucial roles in glioblastoma ( GBM ) carcinogenesis. However, the precise biological function and molecular mechanism of mi R ‐21 in GBM remain elusive. This study is designed to explore the mechanism of mi R ‐21 involved in the control of GBM cell growth. Methods and results MTT assay, cell cycle analysis, and apoptosis analysis showed that reduction of mi R ‐21 inhibited cell growth in U 87 and LN 229 GBM cells. Further, reduction of mi R ‐21 decreased the expression of human telomerase reverse transcriptase (h TERT ) and repressed STAT 3 expression and STAT 3 phosphorylation. STAT 3 inhibition led to a remarkable depletion of h TERT at both m RNA and protein levels by binding to the h TERT gene promoter by performing luciferase reporter assay and chromatin Immunoprecipitation PCR . Finally, knockdown of mi R ‐21 considerably inhibited tumor growth and diminished the expression of STAT 3 and h TERT in xenograft model. Conclusion Our findings indicate that mi R ‐21 regulates h TERT expression mediated by STAT 3, therefore controlling GBM cell growth.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here